Journal of Cancer Research and Clinical Oncology

, Volume 139, Issue 3, pp 429–435

Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer

Original Paper

Abstract

Background

The aim of this study was to investigate whether focal adhesion kinase (FAK) overexpression correlates with lymph node metastases and prognosis.

Methods

The protein expression of FAK was investigated in 153 paraffin-embedded tissues by immunohistochemical analysis and then correlated with various clinicopathologic parameters. FAK mRNA level was detected with quantitative RT-PCR in 57 NSCLC frozen tissues and 20 normal matched tissues.

Results

Immunohistochemistry showed FAK overexpression was significantly associated with positive lymph node metastasis and more advanced disease stage of NSCLCs and adenocarcinoma subtype; real-time PCR also indicated a statistically significant correlation between increased FAK mRNA level and the presence of nodal metastases. Moreover, in survival analysis, FAK overexpression was significantly associated with worse overall survival.

Conclusions

FAK overexpression is a promising pathological factor to predict aggressive behavior and prognosis in patients with NSCLC, particularly in the adenocarcinoma subtype.

Keywords

Non-small-cell lung carcinoma Focal adhesion kinase Metastasis Prognosis 

References

  1. Benlimame N, He Q, Jie S et al (2005) FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 171:505–516PubMedCrossRefGoogle Scholar
  2. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of prognosis. Chest 122:1037–1057PubMedCrossRefGoogle Scholar
  3. Carelli S, Zadra G, Vaira V, et al (2006) Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer. 53(3):263–71Google Scholar
  4. Dunn KB, Heffler M, Golubovskaya VM (2010) Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem 10:722–734PubMedCrossRefGoogle Scholar
  5. Evan G (2010) Getting one’s Fak straight. Dev Cell 19:185–186PubMedCrossRefGoogle Scholar
  6. Frame MC, Patel H, Serrels B et al (2010) The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol 11:802–814PubMedCrossRefGoogle Scholar
  7. Garces CA et al (2006) Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 66:1446–1454PubMedCrossRefGoogle Scholar
  8. Golubovskaya VM, Conway-Dorsey K, Edmiston SN et al (2009a) FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 125:1735–1738PubMedCrossRefGoogle Scholar
  9. Golubovskaya VM, Kweh FA, Cance WG (2009b) Focal adhesion kinase and cancer. Histol Histopathol 24:503–510PubMedGoogle Scholar
  10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRefGoogle Scholar
  11. Hirsch FR, Spreafico A, Novello S et al (2008) The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 3:1468–1481PubMedCrossRefGoogle Scholar
  12. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics 2010. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  13. Kurio N, Shimo T, Fukazawa T et al (2011) Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo. Exp Cell Res 317:1134–1146PubMedCrossRefGoogle Scholar
  14. Lesslie DP, Summy JM, Parikh NU et al (2006) Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 94:1710–1717PubMedGoogle Scholar
  15. Ma WW (2011) Development of focal adhesion kinase inhibitors in cancer therapy. Anticancer Agents Med Chem 11:638–642PubMedCrossRefGoogle Scholar
  16. McLean GW, Carragher NO, Avizienyte E et al (2005) The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 5:505–515PubMedCrossRefGoogle Scholar
  17. Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6:449–458PubMedCrossRefGoogle Scholar
  18. Meng XN, Jin Y, Yu Y et al (2009) Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101:327–334PubMedCrossRefGoogle Scholar
  19. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68PubMedCrossRefGoogle Scholar
  20. Ocak S, Yamashita H, Udyavar AR et al (2010) DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29:6331–6342PubMedCrossRefGoogle Scholar
  21. Ocak S, Chen H, Callison C et al (2012) Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer 118:1293–1301PubMedCrossRefGoogle Scholar
  22. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  23. Provenzano PP, Keely PJ (2009) The role of focal adhesion kinase in tumor initiation and progression. Cell Adh Migr 3:347–350PubMedCrossRefGoogle Scholar
  24. Roberts WG, Ung E, Whalen P et al (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935–1944PubMedCrossRefGoogle Scholar
  25. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  26. Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14:77–94PubMedCrossRefGoogle Scholar
  27. Shibue T, Weinberg RA (2009) Integrin beta1-focal adhesion kinase signalin2010 g directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 106:10290–10295PubMedCrossRefGoogle Scholar
  28. Sieg DJ, Hauck CR, Ilic D et al (2000) FAKintegrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256PubMedCrossRefGoogle Scholar
  29. Slack-Davis JK, Martin KH, Tilghman RW et al (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282:14845–14852PubMedCrossRefGoogle Scholar
  30. Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5:206–219PubMedCrossRefGoogle Scholar
  31. Tomar A, Schlaepfer DD (2010) A PAK-activated linker for EGFR and FAK. Dev Cell 18:170–172PubMedCrossRefGoogle Scholar
  32. Walsh C, Tanjoni I, Uryu S et al (2010) Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 9:778–790PubMedCrossRefGoogle Scholar
  33. Webb DJ, Donais K, Whitmore LA et al (2004) FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 6:154–161PubMedCrossRefGoogle Scholar
  34. Zheng D, Golubovskaya V, Kurenova E et al (2010) A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol Carcinog 49:200–209PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Cancer Institute of Heilongjiang ProvinceHarbin Medical UniversityHarbinChina
  2. 2.Laboratory of Medical GeneticsHarbin Medical UniversityHarbinChina
  3. 3.Department of Chest SurgeryThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  4. 4.Department of PathologyFirst Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations